The historical rank and industry rank for Lineage Cell Therapeutics's Dividend Yield % or its related term are showing as below:
LCTX's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LCTX vs FATE, ABEO, RCKT: Dividend Yield % Comparison
For the Biotechnology subindustry, Lineage Cell Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Dividend Yield % falls into.
Lineage Cell Therapeutics (LCTX) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Lineage Cell Therapeutics and its competitors. According to the industry distribution chart, Lineage Cell Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Lineage Cell Therapeutics' Dividend Yield % too high?
Lineage Cell Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Lineage Cell Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Dividend Yield % compare to FATE and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #999999 out of 151 companies for Dividend Yield %. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.26 — trading 5.3% below its estimated fair value. The current Dividend Yield % is 0.00%. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 5.3% below its estimated GF Value™ of $1.33.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
Dividend Yield %: 0.00%
GF Value™: $1.33 vs. price of $1.26 (5.3% below fair value)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
